Klin Farmakol Farm. 2025;39(3):141-144 | DOI: 10.36290/far.2025.055

Beta-blockers in acute coronary syndrome: current evidence and clinical implications

Anna Chaloupka
I. interní kardio-angiologická klinika Fakultní nemocnice u sv. Anny a Lékařská fakulta Masarykovy univerzity v Brně

Beta-blockers (BBs) have long been a cornerstone of therapy for acute coronary syndrome (ACS). With the advent of reperfusion strategies and modern pharmacotherapy, however, particularly in patients with preserved left-ventricular ejection fraction (LVEF), the role of beta-blockers has become a matter of expert debate. This review summarizes the properties and the role of betablockers in the treatment of acute coronary syndrome, the current guidelines and key randomized trials, and offers a pragmatic framework for the modern indication and duration of beta-blocker therapy across the ACS spectrum.

Keywords: adrenergic beta-antagonists, acute coronary syndrome, myocardial infarction, ejection fraction, percutaneous coronary intervention.

Accepted: October 23, 2025; Published: October 30, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chaloupka A. Beta-blockers in acute coronary syndrome: current evidence and clinical implications. Klin Farmakol Farm. 2025;39(3):141-144. doi: 10.36290/far.2025.055.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Byrne RA, Rossello X, Windecker S, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191. Go to original source... Go to PubMed...
    2. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651. doi:10.1161/CIR.0000000000000617. Go to original source... Go to PubMed...
    3. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β‑blockers for myocardial infarction: a meta‑analysis of randomized trials. Am J Med. 2014;127(10):939-953. doi:10.1016/j.j.amjmed.2014.05.032. Go to original source...
    4. Ibáñez B, Macaya C, Sánchez‑Brunete V, et al. Effect of early metoprolol on infarct size in ST‑segment-elevation myocardial infarction (METOCARD‑CNIC). Circulation. 2013;128:1495-1503. doi:10.1161/CIRCULATIONAHA.113.003653. Go to original source... Go to PubMed...
    5. Roolvink V, Ibáñez B, Ottervanger JP, et al. Early Intravenous Beta‑Blockers in STEMI undergoing primary PCI (EARLY‑BAMI). J Am Coll Cardiol. 2016;67:2705-2715. doi:10.1016/j.jacc.2016.03.522. Go to original source... Go to PubMed...
    6. Chen ZM, Pan HC, Chen YP, et al. COMMIT/CCS‑2 Collaborative Group. Early intravenous then oral metoprolol in 45 852 patients with acute MI. Lancet. 2005;366:1622-1632. doi:10.1016/S0140‑6736(05)67661‑1. Go to original source...
    7. Dargie HJ. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left‑ventricular dysfunction. Lancet. 2001;357:1385-1390. doi:10.1016/S0140‑6736(00)04560‑8. Go to original source...
    8. Yndigegn T, Lindahl B, Mars K, et al. REDUCE‑AMI Investigators. Beta‑Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390(15):1372-1381. doi:10.1056/NEJMoa2401479. Go to original source... Go to PubMed...
    9. Watanabe H, Domei T, Morimoto T, et al. Long‑term carvedilol in STEMI treated with primary PCI (CAPITAL‑RCT). PLoS One. 2018;13(8):e0199347. doi:10.1371/journal.pone.0199347. Go to original source... Go to PubMed...
    10. Silvain J, Cayla G, Ferrari E, et al. ABYSS Investigators. Beta‑Blocker Interruption or Continuation After Myocardial Infarction. N Engl J Med. 2024;391:1277-1286. doi:10.1056/NEJMoa2404204. Go to original source... Go to PubMed...
    11. The Beta‑Blocker Heart Attack Trial (BHAT) Research Group. A randomized trial of propranolol in patients with acute MI. I. Mortality results. JAMA. 1982;247:1707-1714. doi:10.1001/jama.1982.03320370021023. Go to original source... Go to PubMed...
    12. Norwegian Multicenter Study Group. Timolol‑induced reduction in mortality and reinfarction in survivors of acute MI. N Engl J Med. 1981;304(14):801-807. doi:10.1056/NEJM198104023041401. Go to original source... Go to PubMed...
    13. Hjalmarson A, Herlitz J, Holmberg S, et al. Effect on mortality of metoprolol in acute myocardial infarction: Göteborg trial. Lancet. 1981;2:823-827. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.